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W E HAVE previously reported that stable long-term 
survival of hamster heart and liver xenografts is 
successfully achieved in rat recipients by combining contin-
uous tacrolimus treatment and a short induction course of 
antimetabolic drugs.' In this study we further examined the 
immunological status of long-surviving rat recipients of 
hamster heart and liver grafts. 
MATERIALS AND METHODS 
Inored male Lewis rats weighing 200 to 250 g (Harlan Sprague-
Dawley Inc .. Indianapolis. IN) and outored male Syrian hamsters 
weighing 100 to 1:'\0 g (Charles River Lao .. Wilmington. MA) werc 
used for recipients and donors. respective Iv. Heart grafts were 
heterotopically transplanted into the aodomcn or the neck of 
recipients using the methods previously described.v Liver grafts 
were orthotopically transplanted by the modified method of Ka-
mada and Caine." All recipients were treated with intramuscular 
tacrolimus administration at daily doses of I to 2 mg/kg from day 0 
to day 30 with cyclophosphamide (CP) administration at daily oral 
doses of 7.5 to 15 mg/kg from day -I to day I) or 13. Tacrolimus 
was given from 30 days onward in every other day dose of 0.5 mg/kg 
until the time of challenge transplantation and continued indefi-
nitely thereafter in experiments 2 and 3 (see below). 
Experiment 1 
Tacrolimus therapy was stopped 30. 100. and> 150 days after heart 
or liver transplantation. and animals were followed without immu-
nosuppression for another 100 days or until death. 
Experiment 2 
Long-surviving recipients were challenged to accept another ham-
ster graft under continuing reduced-dose tacrolimus. Fifty to 100 
days after the primary hamster heart or liver transplantation, 
recipients were challenged with second hamster grafts. For the 
treatment control. normal Lewis rats' were treated With the same 
immunosuppressive protocol without the primary transplantation. 
and they received the hamster grafts 50 days after the initiation of 
treatment. 
Experiment 3 
Hamster heart grafts surviving more than 50 days under continuous 
immunosuppression were harvested and retransplanted into naive 
Lewis rat recipients. 
RESULTS 
Experiment 1 
All hamster grafts were eventually rejected after the cessa-
tion of maintenance tacrolimus treatment. When immuno-
suppression was stopped at 3D, 100, or more than 150 days 
after transplantation. median drug-free heart xenograft 
survivals were 43.5. 33, and 32 days. respectively. After 
discontinuation of tacrolimus at 30. 100. or > 150 days after 
transplantation. liver grafts survived significantly longer 
than heart grafts for 97 (P = .01).121.5 (P < .05). and 47.5 
days. respectively. 
Experiment 2 
Untreated (Group I. Table I) and treated control recipi-
ents not given primary heart grafts (Group 2) rejected 
challenge hamster heart grafts in 3 days. I n contrast. 
challenge heart grafts were protected from rejection and 
survived for more than 90 days when these had been pro-
ceeded by either a priming heart graft under protocol im-
munosuppression (Group 3) or by a priming liver (Group 4). 
Hamster liver grafts were rejected by untreated recipients 
within 8 days (Group 5). This survival was prolonged to 33 
days by immunosuppression (control Group 6). However. 
liver recipients primed with hearts had median survival of 
85 days (Group 7). Two animals whose survival was 39 and 
97 days had cause of death other than rejection. 
Experiment 3 
Long-surviving hamster heart grafts were normally rejected 
in 4 days when retransplanted into untreated (n = 4) or 
intramuscular tacrolimus (2 mglkg/d) treated (n = 5) naive 
rats. 
DISCUSSION 
As previously reported. I hamster heart and liver transplants 
were able to consistently survive> 100 days with the immu-
nosuppression used in the experiments. However, grafts 
were slowly rejected with the discontinuation of mainte-
nance tacrolimus. even after 100 days. This study also 
showed the same generic phenomena of organ tolerogenic-
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Table 1. Survival of Secondary Challenged Hamster Heart and liver Grafts Transplanted Into Long-Surviving Xenorecipients 
Traatment' SWvival (Second graft) Median SufViva/ 
Group First Graft (tacroI1mus + Cp) Second graftt n (days) (days) P value 
Heart 6 3, 3, 3, 3, 3, 3 3 
2 + Heart 4 3,3,3,4 3 
3 Heart + Heart 7 50, >100 X 6 >100 <.01* 
4 Uver + Heart 5 391, 671, 971, >100 X 2 97 <.02* 
5 Uver 8 6, 7, 7, 7, 7, 7, 7, 8 7 
6 + Uver 2 33,33 33 
7 Heart + Uver 4 41 1,7(1, >100 X 2 85 <.1' 
'Tacrolimus (1-2 mg/kg day) was intramuscularly injected 101' 30 days after first grafting, followed by 0.5 mg/kg injection on every other day thereafter. 
Cyclophosphamide (CP) was given only after first grafting at oral doses of 7.5-15 mg/kg/day (day -1 to 13). 
tSecond grafts wera transplanted between 50 and 100 days after first transplantation. when tacroIimus was injected at a dose 01 0.5 mg/kg/every other day. 
*va Group 2. 
fvs Group 6. 
IAnimai died with functtonlng graft without signs of rejection. 
ity that we recently documented in allografts.s Although the 
liver is known to be more self-tolerogenic than the heart,4.5 
as was evident in the control experiments (compare control 
groups 2 vs 6, Table 1), the best results were actually 
obtained using the heart as the priming organ in the 
experiments described herein. This misleading result was 
caused by late death not related to rejection when the more 
difficult liver replacement was used for either the priming 
(Group 4) or challenge xenotransplantation (Group 7). 
The results strengthen the contention that the same 
principles underlying allograft acceptance apply to xeno-
transplantation, but with a more resistant immunologic 
barrier. 
The tolerogenicity of organ allograft has been associated 
with the chimerism they produce. which in tum simulates 
the effect of leukocyte cell suspensions. We previously 
documented that long-surviving rat recipients of hamster 
organs have such chimerism.6 The retransplantation exper-
iments showed that alteration of the transplanted organ by 
residence in a xenogenic host is insufficient by itself to 
profoundly influence the xenograft reaction. 
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